Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 103-107

  Lim, Sung Chul ^a  

^a Chosun University   (South Korea)

Author keywords

ELISA; Fas L; Gastric adenocarcinoma; Histologic type; sFas L; Tumor stage

Indexed keywords

FAS ANTIGEN; FASL PROTEIN; LIGAND; MEMBRANE PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRECTOMY; HUMAN; METABOLISM; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRECTOMY; HUMAN; IMMUNOENZYME TECHNIQUES; LIGANDS; MEMBRANE GLYCOPROTEINS; MIDDLE AGE; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 0036133903     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.103     Document Type: Article

References (31)

1. Korsmeyer SJ: bcl-2 initiated a new category of oncogenesis: regulator of cell death. Blood 80: 879-886, 1992.
2. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
3. Sager R: Tumor suppressor gene: the puzzle and promise. Science 246: 1406-1412, 1989.
4. Inoue H, Mori M, Honda M, Li J, Shbuta K, Mimori K, Ueo H and Akiyoshi T: The expression of tumor rejection-antigen MAGE genes in human gastric carcinoma. Gastroenterology 109: 1522-1555, 1995.
5. Hoshino T, Seki N, Kikuchi M, Kuramoto T, Iwamoto O, Kodarna I, Koufuji K, Takeda J and Itoh K: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 70: 631-638, 1997. (Pubitemid 27158439)
6. Maehara Y, Tomisaki S and Oda S: Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer. Int J Cancer 74: 224-228, 1997. (Pubitemid 27234515)
7. O'Connell J, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082, 1996.
8. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 3: 294-300, 1997. (Pubitemid 27295100)
9. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC and Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366, 1996. (Pubitemid 26391458)
10. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 2: 1361-1316, 1996.
11. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ and Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 6420-6425, 1997.
12. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
13. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch MC and Tschopp J: Charaterization of Fas (Apo-1, CD95)- Fas ligand interaction. J Biol Chem 272: 18827-18833, 1997. (Pubitemid 27318231)
14. Tanaka M, Suda T, Haze K, et al: Fas ligand in human serum. Nat Med 2: 317-322, 1996. (Pubitemid 26080652)
15. Knipping E, Debatin K-M, Strieker K, Heilig B, Eder A and Krammer PH: Identification of soluble APO-1 in supernatant of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85: 1562-1569, 1995.
16. Midis GP, Shen Y and Owen-Schaub LB: Elevated soluble Fas (sFas) levels in non-hematopoietic malignancy. Cancer Res 56: 3870-3874, 1996. (Pubitemid 26284729)
17. Lauren P: The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 64: 31-49, 1965.
18. Beahrs OH, Henson DE, Hutter RVP and Kennedy BJ: Manual for staging of cancer. 4th edition. American Joint Committee on Cancer (ed). Lippincott, Philadelphia, 1992.
19. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ and Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946, 1995.
20. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A and de Villartay JP: Mutations in Fas associated with with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995.
21. Debatin KM and Krammer PH: Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia 9: 815-820, 1995.
22. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K and Kishimoto T: Myeloma cell express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764, 1995.
23. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580-1586, 1994. (Pubitemid 24106426)
24. Wright SC, Zhong J and Larrick JW: Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 8: 654-660, 1994. (Pubitemid 24198683)
25. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK and Shanahan F: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160: 5669-5675, 1998. (Pubitemid 28267863)
26. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K and Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783, 1995.
27. Sato K, Kimura F, Nakamura Y, et al: An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 94: 379-382, 1996. (Pubitemid 26247999)
28. Mizutani Y, Yoshida O and Bonavida B: Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urolol 160: 571-576, 1998. (Pubitemid 29476736)
29. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K and Hasimoto H: Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40: 1126-1129, 1997. (Pubitemid 27242300)
30. Hosaka N, Oyaizu N, Kaplan MH, Yagita H and Pahwa S: Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J Infect Dis 178: 1030-1039, 1998. (Pubitemid 28452195)
31. Shiota G, Oyama K, Noguchi N, Takano Y, Kataoka S and Kawasaki H: Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pathol Pharmacol 101: 3-12, 1998. (Pubitemid 28439971)